Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Indoximod - NewLink Genetics Corporation

Drug Profile

Indoximod - NewLink Genetics Corporation

Alternative Names: 1 MT; 1-methyl-D-tryptophan; 1-methyltryptophan; d-1-methyltryptophan; D-1MT; NLG-8189; NSC-721782

Latest Information Update: 10 May 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lankenau Institute for Medical Research
  • Developer National Cancer Institute (USA); NewLink Genetics Corporation; University of Minnesota
  • Class Amino acids; Antineoplastics; Indoles; Small molecules
  • Mechanism of Action Indoleamine-pyrrole 2,3-dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Malignant melanoma
  • Phase II Breast cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer
  • Phase I/II Glioma; Solid tumours
  • Phase I Acute myeloid leukaemia

Most Recent Events

  • 08 Aug 2019 Emory University and Augusta University plan a phase II trial in Brain tumours (Combination therapy, Second-line therapy or greater, In children, In adolescents, In adults, Metastatic disease) or Glioma (First-line therapy, Combination therapy, In children, In adolescents, In adults, Metastatic disease) in USA (PO) in September 2019 (NCT04049669)
  • 12 Dec 2018 University of Minnesota completes a phase II trial in Prostate cancer (Metastatic disease, Hormone refractory) in USA (PO) (NCT01560923)
  • 02 Dec 2018 Updated interim efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia released by NewLink Genetics Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top